Nutra Pharma Corp (NPHC) Gross Margin (2010 - 2026)

Nutra Pharma has disclosed Gross Margin across 17 years of filings, most recently posting 94.67% for Q2 2026.

• In Q2 2026, Gross Margin rose 1963.0% year-over-year to 94.67%; the TTM figure through Jun 2026 stood at 64.84% (down 2390.0% YoY), while the FY2025 annual figure was 76.33%, down 2408.0% from the prior year.
• Gross Margin came in at 94.67% for Q2 2026 at Nutra Pharma, up from 69.64% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 276.77% in Q3 2022 to a low of 41.25% in Q4 2025.
• Average Gross Margin over 5 years is 120.06%, with a median of 99.36% recorded in 2026.
• Year-over-year, Gross Margin soared 33174 bps in 2022 and plunged 14701 bps in 2025.
• Over 5 years, Gross Margin stood at 181.67% in 2022, then gained by 10 bps to 199.31% in 2023, then tumbled by 47 bps to 105.76% in 2024, then sank by 139 bps to 41.25% in 2025, then soared by 329 bps to 94.67% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 94.67% in Q2 2026, 69.64% in Q1 2026, and 41.25% in Q4 2025.